Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897908 | 0.79 | NOTUM (0.47) | NOTUMRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL1154499 | 0.78 | MAPT (0.42) | NOTUMRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4308652 | 0.78 | RAB9A (0.40) | NOTUMRAB9ANPC1MEN1KMT2A | |
| SCHEMBL4322903 | 0.78 | ENPP3 (0.42) | NOTUMRAB9ANPC1METAP2MEN1 | |
| SCHEMBL3937636 | 0.78 | AHR (0.48) | NOTUMRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL4307353 | 0.75 | MAPT (0.44) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL4317407 | 0.74 | KIF11 (0.45) | NOTUMRAB9ANPC1MEN1KMT2A | |
| SCHEMBL3283855 | 0.74 | NPC1 (0.46) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL9662582 | 0.74 | KIF11 (0.44) | NOTUMRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL28719886 | 0.74 | KMO (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927560-B2 | 4-Aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-01-06 | — | — | US | claimed |
| EP-2649078-A1 | 4-AZA-2, 3-DIDEHYDROPODOPHYLLOTOXIN COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2013-10-16 | — | — | EP | claimed |
| US-20130245048-A1 | 4-AZA-2, 3-DIDEHYDROPODOPHYLLOTOXIN COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-09-19 | — | — | US | claimed |
| WO-2012076942-A1 | 4-AZA-2, 3-DIDEHYDROPODOPHYLLOTOXIN COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-06-14 | — | — | WO | claimed |
| US-7696181-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2010-04-13 | — | — | US | claimed |
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | IBRAHIM PRABHA | 2009-12-31 | — | — | US | claimed |
| WO-2009137380-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-12 | — | — | WO | claimed |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | claimed |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | IBRAHIM PRABHA | 2006-12-21 | — | — | US | claimed |
| CN-117580824-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| CN-114206848-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-5538940-A | FUNGICIDE, MITICIDE, INSECTICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-23 | — | — | US | disclosed |
| US-5416068-A | Alpha-phenylacrylic acid derivatives, their preparation and their use for controlling pests and harmful fungi | BASF AKTIENGESELLSCHAFT (DE) | 1995-05-16 | — | — | US | disclosed |
| CN-1098713-A | The ortho-ethenylphenylacetic acid derivatives that replaces | BASF AG (DE) | 1995-02-15 | — | — | CN | disclosed |
| US-5298527-A | Insecticides | BASF AKTIENGESELLSCHAFT (DE) | 1994-03-29 | — | — | US | disclosed |
| US-4203896-A | WITH MERCURIC ACETATE AND ACETIC ACID, ACIDIC HYDROLYSIS OF N-PROPENYL GROUP | ELI LILLY AND COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4144232-A | Substituted azetidin-2-one antibiotics | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | ADORA1, ADORA2A, ADORA3 | NOTUM 2984/4885RAB9A 2024/4885NPC1 400/4885 |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | NOTUM 2984/4885RAB9A 2024/4885NPC1 400/4885 |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | NOTUM 4491/4885RAB9A 3313/4885NPC1 2768/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | NOTUM 4491/4885RAB9A 3313/4885NPC1 2768/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | NOTUM 4491/4885RAB9A 3313/4885NPC1 2768/4885 |
| US-20130245048-A1 | 4-AZA-2, 3-DIDEHYDROPODOPHYLLOTOXIN COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | CYP4X1, AZI2, CYP4B1 | NOTUM 2098/4885RAB9A 1253/4885NPC1 3702/4885 |
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, ABCC1, HDAC6 | NOTUM 4303/4885RAB9A 588/4885NPC1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.